Teladoc Health Inc (NYSE:TDOC) posted upbeat results for the fourth quarter on Wednesday.The company posted a quarterly loss of 14 cents per share, versus market estimates of a loss of 18 cents per share. The company's sales came in at $642.269 million, beating estimates of $635.235 million.Teladoc Health said it sees FY2026 GAAP loss of $(1.10)-$(0.70) vs market estimates of $(0.76). The company expects sales of $2.470 billion-$2.587 billion, versus estimates of $2.548 billion.“We closed 2025 with a solid ...

Down 70% over the past year -- and down 60% over just the last three months -- Hims & Hers Health (NYSE: HIMS) stock is in a funk, and Monday night's earnings report didn't help. Shares of the telemedicine company have slid steadily since the FDA announced early last year that Novo Nordisk's (NYSE: NVO) Wegovy and Ozempic GLP-1 weight loss drugs are no longer in shortage. Since that news came out, the writing has seemed to be on the wall for Hims & Hers Health and its business of compounding copycat weigh ...

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended December 31, 2025 (“Fourth Quarter 2025”) and full year ended December 31, 2025 (“Full Year 2025”). Unless otherwise noted, percentage and other changes are relative to the three months ended December 31, 2024 (“Fourth Quarter 2024”) and full year ended December 31, 2024 (“Full Year 2024”). Highlights Fourth Quarter 2025 revenue of $642 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT As filed with the U.S. Securities and Exchange Commission on February 24, 2026. Registration No. 333-291959 UNDER THE SECURITIES ACT OF 1933 Blue Water Acquisition Corp. IV (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Cayman Islands 6770 N/A (Primary Standard Industrial Classification Code Number) (I.R.S. Employer ...

U.S. rate futures have priced in a 95.9% probability of no rate change and a 4.1% chance of a 25 basis point rate cut at the March FOMC meeting.Fed Governor Christopher Waller said on Monday that his decision on whether to back an interest rate cut at the central bank’s March meeting will depend on upcoming labor-market data. “If these data support the idea of an improvement in the labor market in January that continued in February, along with additional progress toward 2% inflation, that could result in my ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on March 9, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Monday, March 9thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-343-5172International Dial-In:203-518-9856Confe ...

Core Viewpoint - Teladoc Health has experienced a significant decline in market value, losing over 98% in the past five years, and is struggling to regain its previous success during the pandemic [1] Industry Overview - Demand for telemedicine services peaked during the pandemic, with usage increasing from 5% pre-pandemic to 42.1% during, and settling at 21.8% post-pandemic, which is still above pre-2019 levels [3] - The telemedicine sector is facing intense competition, particularly from larger corporations like Amazon, which poses challenges for Teladoc's growth, especially in its virtual therapy service, BetterHelp [4] Company Initiatives - Teladoc is attempting to address competition by seeking third-party coverage for BetterHelp to enhance demand and has launched new services such as continuous health monitoring and chronic care [5] - The company is also expanding internationally, with international revenue growing faster than domestic revenue in recent quarters [5] Financial Performance - Despite efforts to grow, Teladoc's revenue is increasing slowly, and the company is currently operating at a loss, with concerns that international expansion may lead to similar challenges as faced domestically [7] - The company has not yet secured broad health insurance coverage for its therapy services, even after acquiring UpLift, which has 100 million covered lives, indicating that third-party coverage does not guarantee demand or revenue [8] Future Outlook - The outlook for Teladoc appears bleak, with significant challenges ahead, and the stock price recently trading at $4.90, raising concerns that it could approach $0 in the next five years [9]

Core Insights - Mangoceuticals, Inc. has reported a month-over-month sales increase of 336% for its newly launched all-inclusive injectable Testosterone Replacement Therapy (TRT) program, which is priced at $99 per month [1][2] - The company has successfully reduced its customer acquisition costs by 54% during the same period, indicating improved marketing efficiency [2] - The global testosterone replacement therapy market is valued at approximately $2.11 billion to $2.2 billion in 2025, with a projected compound annual growth rate (CAGR) of around 3.9% [4] Company Developments - The strong sales momentum for the TRT program reflects growing demand for convenient and effective TRT options, supported by the company's telehealth platform [3] - MangoRx aims to expand its TRT offerings, including both injectable and oral formulations, to capture a larger market share in this high-demand segment [3] - The company is committed to evolving its telehealth platform to provide a broader range of men's health and wellness solutions beyond single treatments [5] Strategic Focus - The CEO of Mangoceuticals emphasized the importance of their innovative approach to men's hormone health and the strategic focus on TRT as a key growth driver [4] - The company plans to build a more comprehensive platform that delivers a wider array of wellness solutions, which is expected to strengthen its operational and financial foundation [4]

Talkspace, Inc. (TALK) shares soared 21.12 percent to $4.7599, up $0.8299 on Thursday, after the company reported sharply higher fourth-quarter net income and revenue, driven by strong growth in its payor segment.The stock is currently trading at $4.7599, compared with a previous close of $3.9300. It opened at $4.5500 and has traded between $4.4300 and $5.1300 during the session on the Nasdaq. Trading volume stands at 6.50 million shares, well above its average volume of 1.27 million shares.For the fourth ...

Core Viewpoint - Earth Science Tech, Inc. has engaged Semple, Marchal & Cooper, LLP as its new independent PCAOB auditor to enhance its financial governance as the company expands its operations in pharmacy compounding, telemedicine, and real estate [1][2]. Group 1: Company Overview - Earth Science Tech, Inc. is a diversified holding company focused on the health and wellness sector, operating a vertically integrated portfolio that includes compounding pharmacies, telemedicine platforms, and healthcare facilities [4]. - The company owns RxCompoundStore.com and Mister Meds, which are licensed compounding pharmacies providing sterile and non-sterile medications across a growing network of U.S. states [4]. - ETST also manages Avenvi, its real estate and asset management arm, and MagneChef, a direct-to-consumer brand for innovative kitchen products [5]. Group 2: Strategic Developments - The transition to Semple, Marchal & Cooper is seen as a strategic upgrade to optimize auditing efficiencies and align with the company's operational scale [2]. - The Board of Directors emphasized the need for a more sophisticated corporate governance framework as the company matures from a developmental stage to a rapidly growing diversified holding company [3]. - Semple, Marchal & Cooper is recognized for its comprehensive suite of services and commitment to long-term growth and integrity, which aligns with ETST's evolving financial needs [3].